Delivery accuracy of VMAT on two beam-matched linacs provided by accelerated go live service.
VMAT
beam data collection
beam matching
commissioning
patient specific QA
Journal
Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
15
05
2023
received:
09
03
2023
accepted:
30
05
2023
medline:
14
7
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
Dosimetric accuracy is critical when a patient treated with volumetric modulated arc therapy (VMAT) is transferred to another beam-matched linac. To evaluate the performance of Accelerated Go Live (AGL) service, the measured beam characteristics and patient specific quality assurance (QA) results between two AGL-matched linacs were compared. Two VersaHD linacs were installed using the AGL service. After the installation, the beam data such as percentage depth dose (PDD), lateral profiles and output factors for all photon beams were measured. Relative doses were also measured as a function of the multi-leaf collimator (MLC) leaf gap width. Subsequently, VMAT plans were created for prostate, pelvis, head and neck, liver, lung cancers and multiple brain metastases. Dose distributions and point doses were measured by multi-dimensional detectors and ionization chambers for patient specific quality assurance, and comparisons were made between the two linacs. Dose differences in PDDs were all within ± 1% except the entrance region, and the averaged gamma indices of the lateral profiles were within 0.3. The differences in doses as a function of the MLC leaf gap width between the two linacs were within ±0.5%. For all the plans, gamma passing rates were all higher than 95% with criteria of 2%/2 mm. The average and the SD of dose differences on the multi-dimensional detector between both measurements was 0.06 ± 2.12%, and the average of point dose differences was -0.03 ± 0.33%. We have evaluated the AGL performance in the context of beam characteristics and patient specific QA. It was demonstrated that the AGL service provides an accurate VMAT treatment reproducibility for many tumor sites with gamma pass rates greater than 95% under criteria of 2%/2 mm.
Identifiants
pubmed: 37327042
doi: 10.1002/acm2.14071
pmc: PMC10338800
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14071Subventions
Organisme : JSPS KAKENHI
ID : JP18K15607
Organisme : JSPS KAKENHI
ID : JP22K15860
Informations de copyright
© 2023 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine.
Références
Acta Oncol. 2009;48(2):192-200
pubmed: 18752079
J Appl Clin Med Phys. 2017 Jul;18(4):23-39
pubmed: 28548315
J Appl Clin Med Phys. 2019 Feb;20(2):51-62
pubmed: 30636358
Med Phys. 2020 Nov;47(11):5852-5871
pubmed: 32969046
Med Phys. 2007 Jul;34(7):2917-27
pubmed: 17822000
Br J Radiol. 2013 Nov;86(1031):20130238
pubmed: 23995874
J Appl Clin Med Phys. 2023 Jul;24(7):e14071
pubmed: 37327042
Med Phys. 2012 Nov;39(11):6981-7018
pubmed: 23127092